$4.49
1.81% today
Nasdaq, Feb 28, 05:21 pm CET
ISIN
US68062P1066
Symbol
OLMA
Sector
Industry

Olema Pharmaceuticals Inc Stock price

$4.41
-1.75 28.41% 1M
-7.27 62.24% 6M
-1.42 24.36% YTD
-9.31 67.86% 1Y
-0.27 5.77% 3Y
-14.59 76.79% 5Y
-14.59 76.79% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.19 4.13%
ISIN
US68062P1066
Symbol
OLMA
Sector
Industry

Key metrics

Market capitalization $301.35m
Enterprise Value $88.29m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.27
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-135.91m
Free Cash Flow (TTM) Free Cash Flow $-96.70m
Cash position $214.76m
EPS (TTM) EPS $-2.19
P/E forward negative
Short interest 16.84%
Show more

Is Olema Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Olema Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Olema Pharmaceuticals Inc forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Olema Pharmaceuticals Inc forecast:

Buy
100%

Financial data from Olema Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.37 0.37
73% 73%
-
-0.37 -0.37
73% 73%
-
- Selling and Administrative Expenses 17 17
1% 1%
-
- Research and Development Expense 118 118
44% 44%
-
-136 -136
35% 35%
-
- Depreciation and Amortization 0.37 0.37
73% 73%
-
EBIT (Operating Income) EBIT -136 -136
34% 34%
-
Net Profit -123 -123
28% 28%
-

In millions USD.

Don't miss a Thing! We will send you all news about Olema Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Olema Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
10 days ago
SAN FRANCISCO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the appointment of Shawnte M. Mitchell, J.D., as Chief Legal Officer and Corporate Secretary.
Neutral
GlobeNewsWire
24 days ago
SAN FRANCISCO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to six new employees to purchase an aggregate of 285,000 shares ...
Neutral
GlobeNewsWire
25 days ago
SAN FRANCISCO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that management will participate in the following investor conferences: Oppenheimer 35 th Annual Health...
More Olema Pharmaceuticals Inc News

Company Profile

Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of targeted therapies for women's cancers. The company also focuses on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is being studied in a Phase 1/2 clinical trial for the treatment of metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.

Head office United States
CEO Sean Bohen
Employees 74
Founded 2006
Website www.olema.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today